Belzutifan

Major

Belzutifan Acetaminophen And Codeine Capital® & Codeine Explained Reduced codeine and morphine exposure, reduced opioid efficacy and precipitation of opioid withdrawal Details Belzutifan Clindamycin ANTIROBE Explained Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Omeprazole Gastrobim Explained Increased belzutifan exposure and an increased risk of belzutifan-related adverse reactions Details Belzutifan Colchicine Colcrys Explained Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Abemaciclib Verzenio Explained Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Abrocitinib Cibinqo Explained Increased belzutifan exposure and an increased risk of belzutifan-related adverse reactions Details Belzutifan Acalabrutinib Calquence Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Asciminib Scemblix Increased belzutifan exposure and an increased risk of belzutifan-related adverse reactions Details Belzutifan Atogepant Qulipta Reduced atogepant exposure Details Belzutifan Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Belzutifan Amlodipine Amvaz® Reduced amLODIPine exposure Details Belzutifan Axitinib Inlyta Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Bosutinib Bosulif Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Brigatinib Alunbrig Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Clindamycin Injection ANTIROBE Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Clindamycin Topical C/T/S® Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Clindamycin Vaginal Cleocin Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Clopidogrel Plavix Increased belzutifan exposure and an increased risk of belzutifan-related adverse reactions Details Belzutifan Cobimetinib Cotellic Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Cyclosporine Injection Atopica Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Cyclosporine Ophthalmic Cequa Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Dasatinib Phyrago Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Dihydroergotamine Injection DHE-45® Injection Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Dihydroergotamine Nasal Spray Migranal Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Docetaxel Beizray Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Docetaxel Injection Beizray Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Dofetilide Tikosyn Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Enasidenib Idhifa Increased belzutifan exposure and an increased risk of belzutifan-related adverse reactions Details Belzutifan Entrectinib Rozlytrek Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Esomeprazole Nexium Increased belzutifan exposure and an increased risk of belzutifan-related adverse reactions Details Belzutifan Esomeprazole Injection Nexium Increased belzutifan exposure and an increased risk of belzutifan-related adverse reactions Details Belzutifan Estradiol Delestrogen An increased belzutifan exposure, an increased risk of belzutifan-related adverse effects, reduced hormonal contraceptives exposur... Details Belzutifan Estradiol Topical Divigel An increased belzutifan exposure, an increased risk of belzutifan-related adverse effects, reduced hormonal contraceptives exposur... Details Belzutifan Estradiol Transdermal Patch Alora® An increased belzutifan exposure, an increased risk of belzutifan-related adverse effects, reduced hormonal contraceptives exposur... Details Belzutifan Everolimus Afinitor Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Belzutifan Felbamate Felbatol Increased belzutifan exposure and an increased risk of belzutifan-related adverse reactions Details Belzutifan Fentanyl Transdermal Patch Duragesic® Reduced exposure of fentaNYL, reduced efficacy of fentaNYL and/or onset of opioid withdrawal symptoms Details Belzutifan Levonorgestrel After banger Reduced levonorgestrel exposure and increased risk of breakthrough bleeding and/or contraceptive failure Details Belzutifan Levonorgestrel Intrauterine System Kyleena Reduced levonorgestrel exposure and increased risk of breakthrough bleeding and/or contraceptive failure Details Belzutifan Lumateperone Caplyta Reduced lumateperone exposure Details